https://www.cancernetwork.com/view/epcoritamab-bla-submitted-to-fda-for-relapsed-refractory-lbcl
Epcoritamab BLA To Be Submitted to FDA for Relapsed/Refractory LBCL | CancerNetwork
Oct 11, 2026 - Patients with relapsed/refractory large B-cell lymphoma may benefit from treatment with epcoritamab, for which a biologics license application will be...
to beepcoritamabblasubmittedfda
https://m.kangbixing.com/tumour/197493.html
艾可瑞妥单抗(Epkinly/Epcoritamab-bysp)用于复发或难治性滤泡性淋巴瘤的CD3/CD20双特异性抗体【康必行海外医疗】
艾可瑞妥单抗 是一种T细胞接合抗体，其作用机制独特：双靶点结合：通过其双特异性结构，一端结合T细胞表面的CD3受体，另一端结合B细胞（包括恶性B细胞）表面的CD20抗原。激活免疫杀伤：这种“桥接”作用将T细胞直接导向肿瘤B细胞，激活T细胞并诱导其对
epkinlyepcoritamab
https://healthtree.org/news/25-fda-approves-epcoritamab-follicular-lymphoma
FDA Approves Epcoritamab Combination for FL
On November 18, 2025, the U.S. FDA approved epcoritamab with rituximab and lenalidomide (R²) for adults with relapsed or refractory follicular lymphoma.
fdaapprovesepcoritamabcombination